AlexanderMLesokhinMD

Hematologic Oncology

Assistant Member, Medicine, Memorial Sloan Kettering Cancer Center

Overview of Dr. Lesokhin

Dr. Alexander Lesokhin is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 15 years. Dr. Lesokhin accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(970) 315-3812

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Albert Einstein College of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2004 - 2025
NC State Medical License 2020 - 2022

Clinical Trials

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant Start of enrollment: 2016 Dec 13
Terminated
Phase 1
A Study of Colesevelam for Lenalidomide-Associated Diarrhea Start of enrollment: 2018 Dec 03
Active, not recruiting
Phase 2
Roles: Contact
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma Start of enrollment: 2019 Nov 19
Active, not recruiting
Phase 2
Roles: Contact
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma Start of enrollment: 2021 Oct 28
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission Start of enrollment: 2020 Jan 03
Recruiting
Roles: Contact
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Start of enrollment: 2017 Oct 25
Completed
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
Journal of Clinical Oncology. 2024-12-04
Evaluating serum free light chain ratio as a biomarker in multiple myeloma.
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, Sham Mailankody, Alexander Lesokhin
Haematologica. 2024-10-03
1 citations
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
Shambavi Richard, Alexander M Lesokhin, Barry Paul, Jonathan L Kaufman, Matthew Pianko
Nature Cancer. 2024-10-01

Abstracts/Posters

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
Alexander M. Lesokhin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Clinical Implementation of PARPi Monotherapy for Prostate Cancer Patients – a US and EU PerspectiveFebruary 15th, 2023
Update from ASCO GI 2023 Ep 2: Lower GI Cancer HighlightsFebruary 2nd, 2023
Role of Immunotherapy Beyond Advanced HCCAugust 17th, 2022
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment